Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 12, 2014, Pages 2265-2272

  Cornelis, F ^a,b   Silk, M ^a   Schoder, H ^a   Takaki, H ^a   Durack, J C ^a   Erinjeri, J P ^a   Sofocleous, C T ^a   Siegelbaum, R H ^a   Maybody, M ^a   Solomon, S B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Biopsy; Cancer; Interventional radiology; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ABDOMEN; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; BONE; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; FEMALE; HUMAN; IMAGE GUIDED BIOPSY; LIVER; LUNG; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING; SUBCUTANEOUS TISSUE;

ABDOMEN; ADOLESCENT; ADULT; AGED; BONE AND BONES; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE-GUIDED BIOPSY; LIVER; LUNG; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SUBCUTANEOUS TISSUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84938507913     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2852-1     Document Type: Article

References (36)

1. Huch K, Roderer G, Ulmar B, Reichel H. CT-guided interventions in orthopedics. Arch Orthop Trauma Surg. 2007;127:677–83. doi:10.1007/s00402-007-0410-z.
2. Lis E, Bilsky MH, Pisinski L, Boland P, Healey JH, O’Malley B, et al. Percutaneous CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy. AJNR Am J Neuroradiol. 2004;25:1583–8.
3. Hiraki T, Mimura H, Gobara H, Iguchi T, Fujiwara H, Sakurai J, et al. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 2009;136:1612–7. doi:10.1378/chest.09-0370.
4. Lechevallier E, Andre M, Barriol D, Daniel L, Eghazarian C, De Fromont M, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology. 2000;216:506–10.
5. Monfardini L, Preda L, Aurilio G, Rizzo S, Bagnardi V, Renne G, et al. Ct-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures. Radiol Med. 2014. doi:10.1007/s11547-014-0401-4.
6. Welch TJ, Sheedy 2nd PF, Johnson CD, Johnson CM, Stephens DH. CT-guided biopsy: prospective analysis of 1,000 procedures. Radiology. 1989;171:493–6. doi:10.1148/radiology.171.2.2704815.
7. Shyn PB, Tatli S, Sahni VA, Sadow CA, Forgione K, Mauri G, et al. PET/CT-guided percutaneous liver mass biopsies and ablations: targeting accuracy of a single 20 s breath-hold PET acquisition. Clin Radiol. 2014. doi:10.1016/j.crad.2013.11.013.
8. Stattaus J, Kuehl H, Ladd S, Schroeder T, Antoch G, Baba HA, et al. CT-guided biopsy of small liver lesions: visibility, artifacts, and corresponding diagnostic accuracy. Cardiovasc Intervent Radiol. 2007;30:928–35. doi:10.1007/s00270-007-9023-8.
9. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, et al. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR. 2009;193:482–9.
10. Jung EM, Friedrich C, Hoffstetter P, Dendl LM, Klebl F, Agha A, et al. Volume navigation with contrast enhanced ultrasound and image fusion for percutaneous interventions: first results. PLoS One. 2012;7:e33956. doi:10.1371/journal.pone.0033956.
11. Tatli S, Gerbaudo VH, Feeley CM, Shyn PB, Tuncali K, Silverman SG. PET/CT-guided percutaneous biopsy of abdominal masses: initial experience. J Vasc Interv Radiol. 2011;22:507–14.
12. Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol. 2007;18:1329–34.
13. Klaeser B, Mueller MD, Schmid RA, Guevara C, Krause T, Wiskirchen J. PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol. 2009;19:1780–5.
14. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007;244:39–47. doi:10.1148/radiol.2441060773.
15. Bitencourt AG, Tyng CJ, Pinto PN, Almeida MF, Meyrellis LC, Pinheiro RP, et al. Percutaneous biopsy based on PET/CT findings in cancer patients: technique, indications, and results. Clin Nucl Med. 2012;37:e95–7. doi:10.1097/RLU.0b013e3182443b78.
16. Yokoyama K, Ikeda O, Kawanaka K, Nakasone Y, Tamura Y, Inoue S, et al. Comparison of CT-guided percutaneous biopsy with and without registration of prior PET/CT images to diagnose mediastinal tumors. Cardiovasc Intervent Radiol. 2013. doi:10.1007/s00270-013-0793-x.
17. Hales NW, Krempl GA, Medina JE. Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? Am J Otolaryngol. 2008;29:113–8. doi:10.1016/j.amjoto.2007.04.006.
18. Tatli S, Gerbaudo VH, Mamede M, Tuncali K, Shyn PB, Silverman SG. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology. 2010;256:305–11. doi:10.1148/radiol.10090931.
19. Ryan ER, Sofocleous CT, Schoder H, Carrasquillo JA, Nehmeh S, Larson SM, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268:288–95. doi:10.1148/radiol.13121462.
20. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, Dupuy 3rd DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–78. doi:10.1097/01.RVI.0000170858.46668.65.
21. Kobayashi K, Bhargava P, Raja S, Nasseri F, Al-Balas HA, Smith DD, et al. Image-guided biopsy: what the interventional radiologist needs to know about PET/CT. Radiographics. 2012;32:1483–501.
22. Nguyen ML, Gervais DA, Blake MA, Mueller PR, Sahani DV, Hahn PF, et al. Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy? AJR. 2013;201:433–8. doi:10.2214/AJR.12.9166.
23. Govindarajan MJ, Nagaraj KR, Kallur KG, Sridhar PS. PET/CT guidance for percutaneous fine needle aspiration cytology/biopsy. Indian J Radiol Imaging. 2009;19:208–9.
24. Wood BJ, Zhang H, Durrani A, Glossop N, Ranjan S, Lindisch D, et al. Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol. 2005;16:493–505.
25. Krucker J, Xu S, Glossop N, Viswanathan A, Borgert J, Schulz H, et al. Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J Vasc Interv Radiol. 2007;18:1141–50.
26. Krucker J, Xu S, Venkatesan A, Locklin JK, Amalou H, Glossop N, et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J Vasc Interv Radiol. 2011;22:515–24. doi:10.1016/j.jvir.2010.10.033.
27. Herbertson RA, Lee ST, Tebbutt N, Scott AM. The expanding role of PET technology in the management of patients with colorectal cancer. Ann Oncol. 2007;18:1774–81.
28. Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N, et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med. 2007;32:429–34.
29. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29–34.
30. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1912–20.
31. Volker T, Denecke T, Steffen I, Misch D, Schonberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–41.
32. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.
33. Ryan ER, Thornton R, Sofocleous CT, Erinjeri JP, Hsu M, Quinn B, et al. PET/CT-guided interventions: personnel radiation dose. Cardiovasc Intervent Radiol. 2013;36:1063–7. doi:10.1007/s00270-012-0515-9.
34. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.
35. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249–54.
36. Ozulker T, Ozulker F, Ozbek E, Ozpacaci T. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 32:265–72. doi:10.1097/MNM.0b013e3283442e3b.